FDA Approves New Manufacturing Process for Alvotech Biosimilar
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
The U.S. Food and Drug Administration granted approval for a new manufacturing process for SIMLANDI®, a biosimilar made by Alvotech. This process, called Process 2.0, is implemented in Alvotech's DSM2 manufacturing suite in Reykjavik, Iceland. The new method more than doubles the drug substance output per batch while maintaining product quality, safety, and efficacy.
From manilatimes.net
Why it matters
The approval increases Alvotech's manufacturing productivity and frees up capacity to support its growing portfolio of biosimilars. This enhanced capacity allows Alvotech to increase supply of its product, which competes directly with HUMIRA.
From manilatimes.net
Who's involved
- AlvotechBiotechnology company developing and manufacturing biosimilar medicines
- FDARegulatory body that granted approval for the new manufacturing process
- Joseph McClellanChief Operating Officer of Alvotech
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- IcelandSpeculative
Iceland might see increased industrial output and economic activity due to higher manufacturing capacity.
- HUMIRASpeculative
HUMIRA could face increased competition in the market due to higher supply from Alvotech.
- AlvotechSpeculative
Alvotech may see increased core manufacturing capacity and potentially positive market price movement.
- NasdaqSpeculative
Nasdaq could experience market price changes based on positive operational news and FDA approval.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- How could Alvotech's new manufacturing capacity affect Millennium Management?Alvotech's capacity boost may improve appeal to investment firms.Likely
- Alvotech's new process could boost biosimilar supply against HumiraIncreased supply of Alvotech's biosimilar may pressure Humira's market share.Likely
- Alvotech's new process may increase competitive pressure on IncyteAlvotech's new process may increase competitive pressure on IncytePossible
- Alvotech's manufacturing boost may increase activity on NasdaqAlvotech's capacity boost may increase activity on NasdaqPossible